Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol | BMJ Open
Lupus landmark trials | PPT
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet Rheumatology
Following Rituximab With Second Biologic Helpful in Lupus | MedPage Today
BEAT-Lupus Clinical Trial - Now Recruiting - LUPUS UK
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial | BMJ Open
PDF) Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: Statistical analysis plan
PDF) Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
Scientists find an indicator in blood that could guide treatment for Lupus
BEAT-Lupus clinical trial shows promise of new treatment for lupus
BEAT-Lupus clinical trial shows promise of new treatment for lupus
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet Rheumatology
PDF) Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
Treatment of lupus nephritis: consensus, evidence and perspectives | Nature Reviews Rheumatology
JCM | Free Full-Text | Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial - UCL Discovery
Promising experimental treatments for lupus nephritis | RRU
PDF) Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
Voclosporin for Lupus Nephritis — NephJC
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation | Nature Reviews Rheumatology
Latest News Archives - LUPUS UK
Laurent ARNAUD on X: "Let's review the design of BLISS-BELIEVE, the phase 3 trial based on the #rituximab + #belimumab combination in systemic #Lupus. The primary endpoint is very ambitious but very
RT @uptoTate: BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if | RheumNow
